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Abstract
Background: Non-islet cell tumor induced hypoglycemia (NICTH) is a very rare phenomenon,
but even more so in gastrointestinal stromal tumors. It tends to present in large or metastatic
tumors, and can appear at any time in the progression of the disease. We present herein a case of
NICTH in a GIST tumor and report an exon 9 mutation associated to it.
Case presentation: A thirty nine year-old man with a recurrent, metastatic gastrointestinal
stromal tumor presented to the hospital with nausea, dizziness, loss of consciousness, and
profound hypoglycemia (20 mg/dL). There was no evidence of factitious hypoglycemia. He was
stabilized with a continuous glucose infusion and following selective vascular embolization, the
patient underwent debulking of a multicentric 40 cm × 25 cm × 10 cm gastrointestinal stromal
tumor. After resection, the patient became euglycemic and returned to his normal activities.
Tumor analysis confirmed excessive production of insulin-like growth factor II m-RNA and the
precursor protein, "big" insulin-like growth factor II. Mutational analysis also identified a rare, 6 bp
tandem repeat insert (gcctat) at position 1530 in exon 9 of KIT.
Conclusion:  Optimal management of gastrointestinal stromal tumor-induced hypoglycemia
requires a multidisciplinary approach, and surgical debulking is the treatment of choice to obtain
immediate symptom relief. Imatinib or combinations of glucocorticoids and growth hormone are
alternative palliative strategies for symptomatic hypoglycemia. In addition, mutations in exon 9 of
the tyrosine kinase receptor KIT occur in 11–20% of GIST and are often associated with poor
patient outcomes. The association of this KIT mutation with non-islet cell tumor induced
hypoglycemia has yet to be established.
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Background
Gastrointestinal stromal tumors (GIST) are rare mesen-
chymal tumors most commonly found in the stomach or
small intestine of adults. Their incidence ranges from 2.1
to 15 per million people, they are evenly distributed
between genders, and 90% are CD-117 positive [1-3].
They usually grow asymptomatically until they are discov-
ered due to appearance of signs and symptoms related to
mass effects, bleeding or bowel perforation [4-6]. Other
very rare clinical manifestations of GIST include hyperpig-
mentation or mastocytosis (both found in inherited
forms of GIST) [7,8] and hypoglycemia [9-12].
Expression of CD-117 is the diagnostic marker for GIST
and is the transmembrane tyrosine kinase receptor also
known as KIT or c-KIT [13]. The ligand for the receptor is
stem-cell factor, which is essential for embryonic develop-
ment and proliferation of a variety of cell types including
melanocytes, gonadal cells, and interstitial cells of Cajal
(GI tract pacemaker cells) [14]. The latter are thought to
be the physiological precursors to gastrointestinal stromal
tumors and their proliferation may be due to unregulated
activation of KIT [15].
To follow is a unique case associating GIST-induced
hypoglycemia due to overproduction of "big" insulin-like
growth factor II with an exon 9 mutation.
Case presentation
A 39 year-old man with a multifocal abdominal recur-
rence of a small bowel gastrointestinal stromal tumor pre-
sented to the hospital following loss of consciousness
preceded by weakness, dizziness and nausea. His serum
glucose was 20 mg/dL (normal 80–110 mg/dL) and
required a continuous infusion of high dose (10%) dex-
trose to maintain a serum glucose concentration above 70
mg/dL. Serologic workup demonstrated no evidence of
factitious hypoglycemia and it discarded the diagnosis of
islet cell-induced hypoglycemia. The insulin like growth
factor (IGF) I and IGF binding protein 3 level were below
the normal range, while insulin, pro-insulin, C-peptide
and IGF II levels were all in the normal range (table 1).
An abdominal computed tomography demonstrated a
large, multicentric tumor with extensive collateral circula-
tion (Fig 1a and 1b). Preoperative selective embolization
of associated vessels was performed to reduce operative
bleeding. The following day, extensive tumor debulking
of both the dominant mass and 99% of the remaining
multifocal 40 cm × 25 cm × 10 cm GIST was achieved (Fig
1c and 1d), obtaining an R1 resection. Immediately after
completing the resection, the patient became euglycemic
without requiring intravenous glucose. The patient was
euglycemic, active and without radiographic evidence of
progression 6 months after his surgery. Due to gastrointes-
tinal intolerance to imatinib, he is currently on therapy
with sunitinib with stable disease.
Pathologic analysis identified the presence of KIT (CD-
117) in the tumor; confirming GIST histology. Extracted
DNA was amplified by polymerase chain reaction for
exons 9, 11, 13 and 17 of KIT. No mutations were found
in exons 11, 13 or 17; however one allele at position 1530
in exon 9 contained a 6 bp tandem repeat insert
(GCCTAT). This led to a duplication of amino acid resi-
dues alanine 502 and tyrosine 503 (Fig 2). The mutation
was confirmed by a TOPO cloning system (Invitrogen,
Carlsbad, California USA), which detected the presence of
one normal allele and one with the 6 bp insert as
described.
The patient's serum and tumor were sent to the University
Medical Center in Utrecht (The Netherlands) for further
analysis. The concentration of II E [68–88] ("big" IGF-II)
in plasma was 51.9 ng/mL (normal: 6.5–17.5 ng/mL).
The levels of IGF binding protein 6 (IGFBP-6) were
reported to be within the normal range. In situ hybridiza-
tion of the tumor samples demonstrated high expression
of IGF II mRNA and elevated pro-IGF II (figure 3).
It has been found that specific KIT mutations in GIST may
predict a patient's prognosis. Mutations on exon 11 are
the most common (79%), while those on exon 9 are only
found in about 11% of GIST. Most patients with exon 11
mutations respond to treatment with imatinib, while less
than half of those with exon 9 mutations respond and are
almost twice as likely to recur [16-18].
The particular mutation we found in our patient has been
reported very infrequently, and is thought to induce a lig-
and-independent gain-of-function with homodimeriza-
tion and constitutive autophosphorylation [19,20]. The
significance of the association of this mutation and non-
islet cell tumor hypoglycemia (NICTH) has yet to be
established.
The incidence of NICTH is thought to be one fourth that
of functional insulinomas (1 case of NICTH per million
people-years) [21,22]. NICTH usually occurs with large or
metastatic tumors that are usually of mesenchymal origin,
but may also present in other types of cancer [23]. Search-
ing via MEDLINE, PubMed, Gold Rush and article cross-
referencing, we only found 4 other publications of NICTH
in GIST; four of which had overexpression of "big" IGF II
and in two there was overexpression of pro-IGF II [9-12].
High concentrations of pre-pro-IGF II genes that are not
properly glycosylated result in the high molecular weight
"big" IGF II. Compared to physiologic IGF II, it has a sig-
nificantly higher affinity to the insulin receptor, and aBMC Cancer 2007, 7:13 http://www.biomedcentral.com/1471-2407/7/13
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Table 1: Initial Evaluation for Sources of Hypoglycemia
Patient's Serum Normal Range
Insulin 2 μU/mL 0–20 μU/mL
Pro Insulin 2.4 pmol/L 2.1–26.8 pmol/L
C-peptide 0.6 ng/mL 1.1–4.6 ng/mL
Cortisol 18 μg/dL 5–25 μg/dL
Chlopropamide 0 μg/mL 0 μg/mL
Tolazamide 0 μg/mL 0 μg/mL
Tolbutamine 0 μg/mL 0 μg/mL
Gyburide 0 μg/mL 0 μg/mL
Glipizide 0 μg/mL 0 μg/mL
Acetohexamide 0 μg/mL 0 μg/mL
IGF Binding Protein-3 1180 ng/mL 1237–2604 ng/mL
IGF-I 40 ng/mL 90–360 ng/mL
IGF-II 391 ng/mL 288–736 ng/mL
IGF = Insulin-like growth factor
1a and b- CT scan of the abdomen and pelvis with oral and intravenous contrast demonstrating a large, multicentric GIST  with extensive collateral circulation extending from the upper abdomen to the pelvis Figure 1
1a and b- CT scan of the abdomen and pelvis with oral and intravenous contrast demonstrating a large, multicentric GIST 
with extensive collateral circulation extending from the upper abdomen to the pelvis. 1c and d- Intraoperative photos of the 
mass being delivered from the abdomen.BMC Cancer 2007, 7:13 http://www.biomedcentral.com/1471-2407/7/13
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lower affinity to its binding protein [24,25]. The associa-
tion of "big" IGF II and NICTH was first identified by
Daughaday in a patient with a fibrosarcoma [26]. Non-
islet cell tumor-induced hypoglycemia secondary to "big"
IGF II is difficult to confirm because laboratory tests for it
are not readily available. A landmark observation by Teale
et al. was that IGF I and II levels in patients with hyperin-
sulinemic hypoglycemia were both usually low, while
patients with NICTH had normal levels of IGF II [25].
Consequently, Hizuka et al. demonstrated that IGF I was
always low in hypoglycemic patients with "big" IGF II,
while those without elevated "big" IGF II had both low
IGF I and II [27].
The management of most patients with NICTH requires
prompt intravenous hydration and glucose infusions.
Once stable, the ideal treatment is to remove the source of
hypoglycemia. In NICTH, the hypoglycemia is not due to
a dysfunctional insulin receptor nor abnormal K-ATP
channels, therefore diazoxide is unlikely to be effective
[28]. Attempts with imatinib as a first-line therapy may
fail due to resistance to the drug, or take as long as 5 weeks
before being able to interrupt the intravenous glucose
infusions [10]. A recent report by Hamberg et al. [12]
found in one patient with NICTH from GIST that elevated
concentrations of imatinib seemed to worsen hypoglyc-
emia, while another patient spontaneously resolved with-
out any GIST-related therapy. Alternative nonoperative
cytoreductive techniques such as selective embolization
and radiofrequency ablation may have a role in alleviating
hypoglycemia; however these have not been reported in
the literature. Additionally, they may potentially result in
greater circulating "big" IGF II during necrosis of the GIST
and may explain Hamberg's findings in a patient treated
with imatinib alone that had hypoglycemia proportional
to the dose of imatinib. In other (non GIST) cases of
NICTH, low dose steroids and growth hormone have
allowed palliative weaning from intravenous glucose
[25,29,30]. Surgical resection remains as the most rapid
and cost-effective therapy to normalize glucose metabo-
lism in most cases of NICTH.
Conclusion
Our experience and review of the literature suggest that a
multidisciplinary approach is helpful in the management
of NICTH in GIST and that prompt surgical debulking is
the treatment of choice.
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